Drug Approval | March 27, 2024
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Combination shows consistent benefit across prespecified post-progression outcomes
Hepatitis B infects over 40 million people in India
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Anand is committed to leading the company's continued commitment to driving innovation in Health Care through the utilization of Digital transformation, AI and LLM
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
The institution will be spread over an area of more than 8 acres
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Subscribe To Our Newsletter & Stay Updated
